Abstract: Temporary drainage of the upper urinary tract by internal ureteral stents is a routine procedure in endourology. However, it is associated with a clear side-effect profile. Our aim was to evaluate prevention and treatment options of stent-related symptoms. We carried out a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines using MEDLINE and SCOPUS, and identified 107 appropriate records. A high number of these studies showed clear methodological limitations. Available data clearly support the use of a 1 -blockers in patients suffering from stent-related symptoms. It seems that antimuscarinic monotherapy or combination with a 1 -blockers might also play an important role, whereas the use of classical analgesics in the treatment of stent-related symptoms has not been assessed systematically within clinical trials so far. Improvements in stent design and material seem to have the potential to reduce stent-related symptoms. However, so far there is no type of stent with outstanding characteristics and clear evidence suggesting fundamental advantages compared with a standard double pigtail stent. Although stent diameter does not seem to influence patients' comfort, it seems to be beneficial to choose a proper stent-length. Coated and drug-eluting stents, as well as intravesical drug application, seem to be promising concepts to prevent stent-related symptoms, but still have to be considered as experimental approaches. Furthermore, thorough patient education has the potential to reduce the morbidity associated with ureteral stenting. Further research in the field seems to be mandatory.
Introduction
Temporary drainage of the upper urinary tract by internal ureteral stents is a routine procedure in endourology. Ureteral stents represent a simple and effective method of ureteral drainage to assure renal function, to treat pain caused by ureteral obstruction and avoid external or visible devices.
However, ureteral stents are associated with a clear side-effect profile. Patients are suffering from LUTS, such as frequency (60%), urgency (60%) and dysuria (40%), 1 as well as pain (80%) 2 and hematuria (54%). 3 Joshi et al. showed that up to 80% of patients report on a reduced QoL as a result of the symptoms arising from ureteral stents, 4 and the procedure is associated with a considerable economic burden. 5 Since internal ureteral stenting was established by Zimskind et al. in 1967 , great efforts have been made to prevent and treat SRS. 6 Although the main focus was on stent design and drug therapy, various other approaches were evaluated including stent positioning and coatings, as well as intravesical drug application. In this context, development and validation of the USSQ in 2003 represented an important step forward. This specific questionnaire assesses the whole spectrum of stent-associated morbidity, and facilitates better comparability of the data in the field. 7 Meanwhile, validated versions of the questionnaire are available in a variety of languages, and the USSQ represents the gold standard in the assessment of SRS.
However, after almost five decades of ureteral stenting, the procedure is still associated with a clearly defined side-effect profile.
In the present systematic review, we provide an overview of the current possibilities to prevent and treat stent-associated morbidity, and outline the available evidence.
Methods
We carried out the present systematic review according to the PRISMA statement. 8 The protocol for the review is available on PROSPERO (CRD42016046371 http://www.crd.york.ac. uk/PROSPERO). MEDLINE and SCOPUS were independently searched by two authors (PB and VZ). Screening for eligibility was carried out in accordance with the Cochrane Handbook for Systematic Reviews of Interventions, followed by cross-checking and clarification of any differences by a third author (DA). The following search terms including the relevant MeSH terms were used: ([ureteral 
Results
After removal of duplicates 11 960 records were identified. After assessment of eligibility, 107 records were finally included in this systematic review. The PRISMA flow diagram is shown in Figure 1 .
Treatment a 1 -Blockers
As a result of our literature search, we found 23 studies on the treatment of SRS with a 1 -blockers. These studies were published between 2006 and 2016, approximately three-quarters were prospective, randomized trials with a control group. Additionally, there were five meta-analyses published between 2010 and 2016.
Deliveliotis et al. published the first randomized trial in 2006, which compared two groups of 50 patients with indwelling ureteral stents. Group 1 received 10 mg alfuzosin once daily for 4 weeks, whereas group 2 received a placebo. All patients completed the USSQ after this time-period. Alfuzosin improved a subset of urinary symptoms and pain. Furthermore, sexual function and general health were less compromised. 9 Two years later, Damiano et al. could also show a positive effect on stent-related urinary symptoms and QoL using tamsulosin as a selective a 1A/1D -adrenoceptor antagonist. 10 In 2014, both tamsulosin and alfuzosin were shown to be equally effective within a double-blind, randomized, placebocontrolled trial by Dellis et al. Furthermore, the authors found that no patients had to discontinue medication because of side-effects in both groups.
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A network meta-analysis published in 2015 also found no statistically significant differences between the two a 1 -blockers. However, according to the results of the rank-probability test carried out, the authors assumed that tamsulosin might be more effective than alfuzosin in patients with ureteral stents. 12 Amongst all trials carried out on a 1 -blockers in the treatment of SRS, there is only a single study that could not show a beneficial treatment effect. In 2015, Park et al. compared the efficacy of tamsulosin, solifenacin (oral antimuscarinic) and combination therapy of both agents within an open-label, randomized controlled trial, and found no beneficial effects for all of the groups. 13 However, that study had some important limitations, including the absence of placebo use in the control group, open-label design and especially the use of 0.2 mg tamsulosin instead of the standard dosage (0.4 mg).
The most recent meta-analysis in the field was carried out by Zhang et al., 14 and included 14 studies and a total of 1075 patients. Similar to the meta-analyses carried out before, the pooled data showed significant advantages of a 1 -blockers regarding the USSQ subscores for urinary symptoms, pain and general health, as well as the USSQ and IPSS QoL score, and IPSS voiding symptoms. In contrast, no significant decrease of IPSS storage symptoms and the USSQ subscores for sexual matters, work performance and additional problems could be detected for the use of a 1 -blockers.
Possible bias in some of the studies carried out so far especially arises from the use of non-validated questionnaires, trial design (not blinded, no placebo, not randomized) and the missing assessment of patients' medication compliance.
However, the existing data clearly supports the use of a 1 -blockers in patients suffering from SRS (Table 1) .
Antimuscarinics
As patients suffering from SRS often report on symptoms similar to overactive bladder (i.e. frequency, urgency, urgeincontinence), antimuscarinics have been widely used "offlabel" to treat SRS for many years in clinical practice. The first trial systematically investigating the influence of an antimuscarinic drug on SRS was published in 2008. Norris et al. compared the effects of ER oxybutynin, phenazopyridine and placebo within a randomized, double-blind trial, and found no significant differences regarding urinary symptoms and pain. 15 However, the study was clearly underpowered and, thus, declared as inconclusive.
Although their study was underpowered, too, Park et al. found a significant reduction of the USSQ scores for urinary symptoms and pain for tolterodine ER in 2009. 16 Subsequently, there were just a few trials assessing the efficacy of antimuscarinics (i.e. solifenacin, tolterodine) alone or in combination with a 1 -blockers. [17] [18] [19] These trials were summarized in a meta-analysis by Zhou et al. in 2015. 20 The authors concluded that antimuscarinics alone improve IPSS total score as well as QoL and VAPS, and that combination therapy with a 1 -blockers seems to be superior compared with the respective monotherapies. However, because of limited data, heterogeneity between the trials (i.e. drug therapy regimens, duration and indication of stent) and underreporting of adverse events, they also emphasized the need for further trials in the field.
Recently, two trials with contradictory results have been published. On the one hand, Park et al. compared the effects of tamsulosin, solifenacin and their combination. 13 As described above, none of the groups showed improvement of SRS compared with an untreated control group. On the other hand, El-Nahas et al. published a randomized controlled trial including 131 patients comparing tamsulosin (0.4 mg) and solifenacin (5 mg) with a placebo. 21 Total USSQ score 1-2 weeks after stent insertion was 61 in the solifenacin group, 76 in the tamsulosin group and 83 in the control group (P < 0.001), and all USSQ domains, except sexual matters, were significantly better in the solifenacin than in the tamsulosin group (P < 0.05).
Summarized, there are fewer data for the use of antimuscarinics in patients suffering from SRS than for a 1 -blockers, and further studies are required. However, it seems that antimuscarinic monotherapy or combination with a 1 -blockers might play an important role in the treatment of SRS.
Mirabegron
Considering the efficacy of antimuscarinics, a potential role of mirabegron in the treatment of SLS seems to be plausible. No such trials are available, so far. However, at least three clinical trials are in progress (NCT02744430, NCT02095665, NCT02462837).
Analgesics
Pain represents one of the most bothersome problems associated with ureteral stents, and has been reported to occur in up to 80% of patients. 2 The bladder area, lumbar region, flank, groin and genitalia are the most common sites of pain, and lead to an impairment of physical activities in the majority of patients.
2 Surprisingly, the present systematic literature review revealed no trials assessing the influence of classical analgesics on SRS. Substances, such as paracetamol, 
Prevention

Stent materials and design
Various types of ureteral stents are available for clinical use, and differ in their composition, construction geometry and design, and many of them have been designed with the intention to improve patients' comfort. We identified 33 records assessing the correlation between stent design and associated SRS. Many of these studies have clear limitations, which might be one of the reasons for partially contradictory results ( Table 2 ). The first trial assessing the influence of stent rigidity was published by Pryor et al. 22 The authors found no significant differences in SRS for four stent types with different rigidity. In 1995, Lennon et al. reported on a significantly higher incidence of dysuria, renal and suprapubic pain in the group with firm stents compared with a softer stent within a randomized trial including 155 patients. 23 However, they did not find any differences regarding the incidence of urgency, frequency, nocturia or hematuria.
In 2005, Lee et al. randomized 44 patients to compare five different types of stents (Table 2 ) using the USSQ and narcotic diaries on day 1, 3 and 5 after stent placement. 24 No significant differences could be found for pain and USSQ total score or narcotic use. A significant improvement of the urinary symptoms score could only be shown for the Inlay stent on day 3. All of these studies had clear statistical limitations (i.e. absence of power analysis, no correction for multiple testing).
In 2005, Joshi et al. compared a firm and a soft polymerstent (Percuflex vs Contour; Boston Scientific, Natick, MA, USA) in a prospective randomized single-blind study. 25 According to sample size calculation, 116 patients were analyzed using the USSQ as the primary outcome measure at 1 and 4 weeks after stent insertion. The authors found no significant differences regarding urinary symptoms, pain, general health and work performance at both times, and concluded that stent composition alone does not seem to influence patient comfort and overall ureteral stent experience. Consistent with that, Davenport et al. found no significant differences in 129 patients randomized to insertion of either an InLay stent (Bard Medical, Covington, GA, USA) or the Polaris ureteral stent (Boston Scientific), which has a softer composition of the distal stent material. 26 In contrast to these trials, Lee et al. described advantages of the Polaris stent regarding total IPSS and storage symptom subscore, as well as mean VAPS. 27 Besides stent rigidity, many authors focused on stent design (Table 2) . Particular importance was attached to the intravesical stent end, which is commonly held accountable for urinary symptoms and bladder pain. Thus, Dunn et al. evaluated a stent with a 7-Fr proximal end tapering to a softer lumenless straight 3-Fr tail at the distal end. 28 The authors reported on significantly fewer overall irritative voiding symptoms, though urgency, dysuria and pain did not differ significantly compared with the group with conventional 7-Fr stents.
The concept of material reduction within the bladder was further developed, leading to a stent with a conventional pigtail design (5-8-Fr) proximally and very soft 2.1-Fr loops intravesically. This novel design was assessed in 2009 by Lingeman et al. within a multicenter trial. 29 The authors randomized 236 patients in a 1:1:1:1 ratio to short loop tail stents, long loop tail stents, Percuflex Plus and Polaris stents. Although the study showed slight advantages of the short loop tail stent regarding the USSQ pain score, it was terminated early, as interim analysis showed no significant differences between the study arms. The short indwelling time of the stents (mean 4.1 days) was emphasized as a clear limitation of this otherwise well-designed trial. On the contrary, Kawahara et al. reported on a reduction of most urinary symptoms, as well as pain changing from conventional stents to the loop tail stent (Polaris Loop; Boston Scientific). 30 However, their study had clear methodological limitations (Table 2 ). Vogt et al. refined the approach of reduced intravesical material, and replaced the lower part of a double-pigtail stent with a 0.3-Fr suture. 31 The authors reported on significantly improved urinary symptoms in a case series of 79 patients. Remarkably, the patients undergoing secondary endoscopic interventions presented a clear dilatation of the ureteral meatus and the whole ureter. Transsphincteric migration of the suture was found in 13 of the patients, but did not cause symptoms.
Furthermore, the use of antireflux valves was proposed to reduce symptoms arising from vesicoureteric reflux facilitated by the stent. Ecke et al. reported on less flank pain and bladder pain during voiding in 72 patients undergoing insertion of antireflux stents compared with 61 patients with conventional stents. 32 Their study was randomized and single-blind, but assessment was carried out with three self-developed questions instead of a validated questionnaire, and a sample size calculation was not reported. In 2012, Ritter et al. reported on their first experiences with a newly developed antirefluxive stent in a small randomized trial (n = 29). 33 They used a non-validated translation of the USSQ and found slight advantages compared with conventional stents, which were not significant.
Multilength stents were primarily established to reduce stock holdings of different stent lengths. Calvert et al. randomized 113 patients to receive multilength or conventional 24-cm ureteric stents. Using the USSQ, the authors did not find any differences between the two groups. 34 Summarized, it seems that the potential of current stent designs and materials to reduce SRS is limited, and the ideal stent is still yet to be developed.
Stent length and position
Positioning of the proximal stent loop (i.e. renal pelvis vs upper calix) is generally supposed to have no influence on the extent of SRS. We only identified one record assessing the impact of the proximal stent location. Liatsikos et al. randomized 40 patients to positioning of the upper coil in the upper pole or in the renal pelvis. 35 Using a self-developed questionnaire, they found significant lower urgency, less dysuria and a better QoL for stents placed in the upper pole. However, the same stent length (26 cm) was used for all patients. Thus, the results might be influenced by intravesical stent length, which was not assessed in the study.
As discussed above, the intravesical part of the stent is suspected to be responsible for urinary symptoms as well as bladder pain. Shorter stent ends, not crossing the midline of the bony pelvis were shown to cause fewer SRS in several studies. Rane et al. reported on an increased incidence of urinary frequency in patients with stents crossing the midline of the bony pelvis for the first time in 2001. 36 In their prospective assessment of 60 patients, they used a self-developed questionnaire, and additionally identified incomplete bladder loops as a predictor of SRS.
Al Kandari et al. compared 60 patients with proper stent length (i.e. proximal end in renal pelvis, distal end just beyond vesicoureteral junction) with 60 patients with longer stents (i.e. proximal end at upper calix, distal end crossing midline of the bladder) within a randomized trial. 37 Using a self-developed questionnaire, they found significantly fewer urinary symptoms and a better QoL in patients with shorter stents, whereas they found no differences for flank pain and hematuria. Ho et al. confirmed these results in a prospective series of 87 patients. 38 Giannarini et al. were the first to investigate this question using the USSQ. 39 They tried to identify predictors of morbidity in a prospective evaluation of 86 patients undergoing temporary ureteral stenting. In a multivariate analysis, the location of the distal stent loop showed the strongest association with most of the USSQ-domains at both 7 and 28 days after insertion.
These data support the assumption that shorter intravesical stent ends are associated with fewer SRS. However, there is conflicting data, too. Besides the trial by Lingeman et al. 29 that could not even show significant advantages for markedly reduced intravesical stent material discussed above, our own study group recently could not find an influence of intravesical stent position on the associated morbidity as measured by USSQ total score and subscores. 40 Remarkably, this prospective assessment of 73 patients showed a high flexibility of the stent location during the indwelling time, bringing the approach to assess the intravesical stent position by X-ray into question.
Summarized, the majority of trials points at advantages of shorter stent ends within the bladder (Table 3) . Although, as suggested by Giannarini et al., further well-designed trials seem to be mandatory to determine which stent characteristics are definitely responsible for SRS, the choice of a proper (i.e. shorter) stent length seems to be shown in clinical practice. 39 
Stent diameter
In 1997, Candela et al. were the first to investigate the influence of stent diameter on SRS. 41 They did not find any differences between 4.8-Fr and 6-Fr stents regarding urinary symptoms and pain. However, their study had some limitations (i.e. small sample size, no randomization, no validated questionnaires). In 2003, Erturk et al. randomized 46 consecutive patients to receive either 4.7-Fr or 6-Fr ureteral stents in a single-blind study. 42 Pain and different irritative symptoms were evaluated using a scale from 0 to 5, and did not show differences in both groups. These findings were confirmed by a further small non-randomized trial by Damiano et al. 43 Furthermore, other studies investigated stent diameter as a secondary outcome measure, and found no influence on the associated SRS. 39, 44 Summarized, although there is a lack of well-designed trials of adequate power, it seems that SRS cannot be influenced by stent diameter.
Stent coatings
Bonkat et al. showed a significant association between biofilms on ureteral stents and the incidence of lower urinary tract symptoms. 45 Thus, stent coatings inhibiting the formation of biofilms might also have the potential to reduce SRS. In this context, triclosan represents the most extensively investigated substance. In 2009, Cadieux et al. investigated eight patients undergoing long-term ureteral stenting. 46 After 3 months, a control stent was replaced by a triclosan-eluting stent for another period of 3 months. In this small prospective case series, the triclosan stent showed no advantages in urine and stent culturing, biofilm formation, and encrustation development. However, fewer symptomatic episodes and a reduced prescription of antibiotics were found with the triclosan stent, which was interpreted as a potential reduction of urinary symptoms as a result of anti-inflammatory effects of triclosan. Thus, the same study group randomized 20 patients undergoing short-term stenting (7-15 days) to receive either a Triumph triclosan-eluting or a control stent. 47 Though they did not find an impact on biofilm formation, the Triumph stent led to a significant reduction of several SRS, which was ascribed to an anti-inflammatory effect of triclosan. Use of a 3-day antibiotic prophylaxis in the control group, non-validated questionnaires and a small sample size must be issued as limitations of this trial.
Although a reduction of biofilm formation has been reported for other different stent coatings in vitro 48, 49, 50 and in vivo, 51 our literature search revealed no clinical studies investigating the potential of such coatings to reduce SRS.
Beside the inhibition of biofilm formation, a local supply of the affected organs with analgesic or anti-inflammatory drugs represents another concept of drug-eluting ureteral stents. Krambeck et al. investigated the potential of a ketorolac (reversible inhibitor of COX-1 and -2)-coated stent. 52 In a randomized, multicenter, double blinded clinical study, 276 patients underwent stenting with a Percuflex Plus stent with or without ketorolac trimethamin loading. The authors did not find an advantage in unscheduled physician contacts, early stent removals, pain medication changes (defined as primary end-point) nor VAS assessed pain, patient satisfaction and pain medication use (secondary endpoints), although they identified a sub-group of patients (i.e. younger males) that required less pain medication immediately after surgery. A major limitation of this well-designed trial was the use of VAS and satisfaction assessments instead of the USSQ.
As a summary, there might be a role of coated and drugeluting stents to reduce SRS. However, this approach is limited by high production costs, as well as insubstantial clinical effects in the trials carried out so far, and there is no stent coating that can be clearly recommended at the moment.
Intravesical instillations or injections
Three records assessing the efficacy of intravesical agents in the prevention of SRS could be found.
In 2004, Beiko et al. enrolled 42 patients in a double-blind randomized study comparing the efficacy of intravesical instillation of three agents (oxybutynin, alkalinized lidocain, ketorolac) or 0.9% sodium chloride as a control solution. 53 The application was carried out immediately after stent insertion. The authors used a self-developed questionnaire, and reported on a significant decrease in flank pain 1 h after the procedure for ketorolac and oxybutynin. In contrast, the mean VAS-based urinary symptom 6 scores for the four groups showed no differences in SRS and the study had some key limitations (i.e. small sample size, non-validated questionnaire, inconsistency in anesthetic agents administered throughout the study).
Another randomized, controlled single-blind study by Sur et al. investigated the efficacy of five injections of 2 mL 0.5% ropivacaine around the ureteral orifice. 54 Compared with a control group that underwent injections of normal saline in identical locations, they found slightly decreased pain and voiding symptoms 8 h postoperatively until the day of stent removal. None of the symptoms assessed was significantly improved, and the study had some major limitations (i.e. small sample size [n = 22], non-validated questionnaire, differing baseline characteristics of both groups).
Postulating that stent symptoms arise from detrusor muscle spasm located around and in the intramural ureter, Gupta et al. evaluated the effect of botulinum toxin type A injections (10 U/mL to three locations around the ureteral orifice; n = 30) versus no injection (n = 21) after unilateral ureteral stent insertion. 55 This randomized, single-blind study showed a significant decrease in pain and less narcotic use in the treated group, whereas none of the USSQ subscores improved.
In conclusion, the potential of intravesical instillations and injections in the prevention of SRS seems to be limited, but cannot be estimated conclusively because of a lack of available data.
Other methods of prevention
Patient education: Based on the assumption that anxiety and stent-related discomfort might be reduced by thorough patient education, our own study group carried out a prospective study including 74 patients. We found that patients that were given more education regarding SRS showed a significant reduction of the USSQ total score, as well as the subscore for urinary symptoms. 56 Furthermore, they felt less mentally strained (as measured by USSQ items G3, G4), and less reluctant to undergo ureteral stenting in the future (GQ). Although with a correlation of À0.40 (P < 0.001) the influence of information on the incidence and extent of SRS seems to be limited, it appears to be worthwhile to invest enough time in a thorough patient education.
Discussion
Our systematic literature search revealed a high number of studies assessing methods of treatment and prevention of ureteral stent-related morbidity. The variety of methods aiming to reduce SRS raises the question, which method of treatment or prevention has the greatest potential and works the most effectively? Like carried out before for drug treatment of SRS, the initial object of our systematic review was to perform a network meta-analysis comparing the potential of the different methods of treatment and prevention described above. 12 RCTs were further checked for eligibility to be included in that network meta-analysis. Inclusion criteria were: (i) study assesses measures to treat or prevent SRS; (ii) standard indications for ureteral stenting; and (iii) use of USSQ, and reporting of at least urinary symptoms score and body pain score. However, aside from eight trials assessing drug treatment, which were already the subject of the metaanalyses described above, 12, 14 just two further studies 25, 26 met the inclusion criteria. Although many of the trials using the USSQ did not provide the actual numbers for USSQ total score and subscores, the remaining studies applied a multiplicity of tools to assess stent-related morbidity (i.e. selfdesigned questionnaires, IPSS, QoL, OABSS, VAPS), which prevents a systematic comparison. Therefore, a meta-analysis was not possible, and the present review had to be carried out in a narrative form.
In addition, a conspicuous number of trials carried out in the field show methodological limitations, such as missing sample size calculations, inadequate trial designs and underreporting of medication compliance. Furthermore, the USSQ should be consequently applied in future trials to assess the whole spectrum of stent-associated morbidity, and to facilitate comparison of different trials as well as meta-analyses.
Naturally, prevention of SRS would render their treatment unnecessary and, thus, seems to be of major importance. However, the possibilities to prevent SRS seem to be limited. Existing data suggest that improvements in stent design and material might have the potential to reduce SRS. However, so far there is no type of stent with outstanding characteristics and clear evidence suggesting fundamental advantages compared with a standard double pigtail stent. Although stent diameter obviously does not influence patients' comfort, it seems to be indicated to choose a proper (i.e. shorter) stent-length. Nevertheless, the actual significance of stent length and position should be the objective of further well-designed trials. There also might be a future role of coated and drug-eluting stents, as well as for intravesical drug application. At present, these concepts rather represent experimental approaches that have to be further investigated, and the associated costs still constitute a major drawback. Finally, a thorough patient education about possible SRS is not only advisable for ethical reasons, but also has the potential to reduce the associated morbidity. 56 With the limited possibilities to prevent SRS, their treatment becomes even more important. In this context, a 1 -blockers have been investigated most extensively, and can be clearly recommended for patients suffering from SRS.
Furthermore, antimuscarinics seem to have their place in the treatment of SRS. However, their efficacy compared with a 1 -blockers, as well as their potential as a combination therapy, should be the objective of further studies. Classical oral analgesics have always played an important role in the treatment of stent-associated pain. Though they are mentioned as possible confounders in many of the trials discussed above, there are no data assessing their efficacy in the treatment of SRS.
Conclusions
After almost five decades of internal ureteral stenting, this endourological standard procedure is still associated with a clear side-effect profile. Thus, ureteral stents should be avoided whenever possible, and removed as soon as possible. However, ureteral stenting remains unavoidable in a considerable number of our patients. In these cases, a proper stent length should be chosen, and patients should be informed thoroughly about potential side-effects and treated with analgesics, a 1 -blockers or antimuscarinics whenever necessary. Further studies in the field, and novel concepts to treat and prevent SRS are mandatory.
